UAE says Sinopharm vaccine has 86% efficacy against COVID-19
DUBAI (Reuters) - An experimental coronavirus vaccine developed by China’s Sinopharm has 86% efficacy against the virus, the United Arab Emirates health ministry said on Wednesday, citing an interim analysis of a human trial underway there.
The Gulf Arab state in July started Phase 3 clinical trials of the vaccine, developed by Beijing Institute of Biological Product, a unit of Sinopharm’s China National Biotec Group (CNBG). In September, the UAE approved its emergency use for certain groups.
The analysis also shows “99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease”, the ministry said in a statement carried by the state news agency.
“The analysis shows no serious safety concerns,” it said.
It also said it had officially registered the vaccine, without elaborating, and that 31,000 volunteers across 125 nationalities participated in the UAE trial.
United Arab Emirates Claims China’s Sinopharm Vaccine Is 100% Effective At Preventing Moderate And Severe Covid-19
TOPLINE The experimental vaccine developed by China National Pharmaceutical Group, also known as Sinopharm, is 86% effective at preventing Covid-19 infection and 100% effective at preventing severe and moderate disease, health officials from the United Arab Emirates announced Wednesday, although with scarce detail provided about the trial.
The UAE health ministry cited an interim analysis of a late-stage clinical trial involving 31,000 volunteers as the source of its information, though neither they nor Sinopharm provided any data from the trial to validate the claims such as how many participants were infected or how many actually received the vaccine.
The ministry said “no serious safety concerns” were observed, though, again, no information on side effects was provided.
The ministry said the announcement is a “significant vote of confidence by the UAE’s health authorities in the safety and efficacy of this vaccine.”
The ministry added that it had officially registered the vaccine at the request of the manufacturer, which it says could eventually lead to the shot’s widespread authorization.
Nothing is easy in life, if so easy everyone win money and no one lose money in stock market liao. I think we can afford wait a little longer and set cut loss if the price continue to go down. Just hope all of us who invested in TITI ends 2020 with some lucky break.
Salman, nothing much will happen until Sinopharm vaccines receive the approval. From AGM, the CFO already mentioned that updates will come only after vaccines are approved.
Sinopharm submitted the application end of Nov. Hopefully by year end China government can approve the vaccines.
Chances for Npra to approve will be very high once China clear the vaccines. UAE has approved Sinopharm vaccines so I’m pretty sure Sinopharm vaccines are halal.
I don’t think operator pressing down lol. Volume less than 20k traded today. What kinda operator is that? Ikan bilis punya operator or anak berudu punya operator? Haha
X3sphere, when someone try to press down the price, there will be very little volume for Titijaya because other than contra or weak holders, not many are willing to sell cheap now in view of the huge potential upside Titijaya has.
Actually buying at such low price level is really a good bargain. Titijaya is a profit making company by its property business itself and now with the new business diversification and the potential future vaccine deals with Sinopharm, current price levels are really a big big discount of Titijaya’s full potential.
The recent announcement of ICPS conversion price of 0.825 is a great reminder to everyone that someone is willing to pay 0.825 for Titijaya shares!
With this ICPS conversion price of 0.825, something big is brewing and only insiders know... Welcome to comment if any insiders here... (We won't expose you to Authorities)
Chan8, Peru just temporarily suspended the trial. All other vaccines for example Pfizer, Moderna, J&J, etc all experienced suspension during the trials over past months.
Sinopharm vaccine trials in Peru involving around 12,000 people and only one of their participants (in trials) presented neurological symptoms which could correspond to a condition called Guillain-Barre syndrome
According to report, there are over 1 million people across the globe are on Sinopharm vaccine trials. So only one case of potential adverse impact is really insignificant.
Once they find out the reason, which likely not to be related to the vaccine. Then the trials will continue as planned.
Not promoting buy call for the above counter Luxchem.
But this should be the way how someone be sharing facts about a counter based on their financial records, market sentiment and upcoming forecast beside just wild imagination and baseless prediction.
Agree... suspending vaccine trial should not be a worry cause it’s only affecting only minimal people count.
Recent IPCS conversion it’s 10,000 shares which mean 10 units x RM825 = RM 8250?
Or It’s 10,000 units x RM8250 = 8.25M?
How many such IPCS for the last 6 months and is the volume much more than this time?
Readers Kindly check the facts to justify yourself is this something big coming. I am not against anyone but merely referring to the facts clearly announce on Bursa
As usual U just continue to comment I am from operator poring cold water and spreading fear........whatsoever you prefer to label me
Great news! After UAE, Bahrain become the second country that officially approve Sinopharm vaccines for public usage! Not emergency usage but PUBLIC USAGE!
China’s approval should be over next few days too!
No kepala pusing lah , is only about what entry price u bought at that time . I still make some small profits and actually when the price shot up to 60 over cents , l hesitate to sold and then it went down and since then , the price going lower and lower and stagnant
From recent price trend and queuing volume, ‘someone’ is trying to press down prices to frustrate people like old china man, maridien and small prawn to sell cheap. Actually it’s a good sign, if you’re experienced enough in market.
My advice is just hold on and believe Tan Sri Lsp and his team. Buying Titijaya at this level is fairly safe with limited downside and huge potential upside. My gang ready 50-100 mil cash to buy more Titijaya from the ‘someone’ when the someone presses price down more. Good opportunity.
No announcement because Titijaya intention is to con people. The same reason why no follow up after signed ppe agreement in April and gloves agreement in Aug. Not even one ppe and glove imported or exported.
Someone intention is to drag and let people lose patient and those impatient ones will sell cheaply to those who are waiting at lower prices now. The question is how long can they drag? Sinopharm vaccines approval are coming and PM is under pressure to quickly bring more vaccines into Malaysia. Time is running out and that’s why the someone is getting more desperate to buy back shares that they sold during high time.
If u think there is great potential then why not buy at 0.405 or 0.410. Surely the limit up later on will make the current price look like peanut right?
The operator won't let us earn their money so easily that is why most punters lose money in stock market.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: Building management systems (BMS), solar thermal systems and energy-saving services provider, Solar District Cooling Bhd aims to list on the Ace Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
NPRA1985
3,415 posts
Posted by NPRA1985 > 2020-12-09 10:39 | Report Abuse
@Friendship Titijaya will go down to 0.01 then lol